December 28, 2021 Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read More
December 7, 2021 Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update Read More
December 1, 2021 Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit Read More
November 12, 2021 Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update Read More
November 11, 2021 Gain Therapeutics Presents Parkinson’s Disease Preclinical Study Results at Society for Neuroscience Annual Meeting Read More
November 10, 2021 Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small Molecules for the Treatment of Parkinson’s Disease and Gaucher Disease Read More
November 4, 2021 Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference Read More
October 26, 2021 Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB) Read More
October 12, 2021 Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration Read More
September 23, 2021 Gain Therapeutics to Present at the Cantor Virtual Global Healthcare Conference Read More
September 17, 2021 Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Read More
September 9, 2021 Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference Read More
September 8, 2021 Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease Read More
September 2, 2021 Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Read More
August 11, 2021 Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update Read More
May 17, 2021 Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May Read More
May 3, 2021 Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress Read More
April 27, 2021 Gain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference Read More
April 22, 2021 Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress Read More
April 20, 2021 Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals Read More
March 25, 2021 Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares Read More
March 18, 2021 Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock Read More
March 10, 2021 Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering Read More
February 11, 2021 Gain Therapeutics Presents Positive Pre-Clinical Data Supportive of In Vitro Target Engagement for Gaucher Disease, GM1 Gangliosidosis and Morquio B Programs at the 17th Annual WORLDSymposium™ Read More
February 4, 2021 Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium Read More
